Paolo CaimiMD
BAFF CAR-T(Paolo Caimi, MD)은 FRα 표적 세포·유전자 치료로, Relapsed CLL; Refractory CLL 영역에서 개발·상용화 중입니다. 작용기전: targeting CAR T cells eliminate antigen. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 15건의 관련 임상이 등록되어 있습니다. 차별점: Novel therapies that suppress pathogenic antibody production or accelerate their clearance-such as B-cell depletion therapy,.
FRα
Relapsed CLL; Refractory CLL
Recruiting
CAR T cells eliminate antigen-low myeloma in an immunocompetent m
AAV) is now recognized as a complex immune-mediated inflammatory disorder rather th
humanized mouse model developed by injecting patient PBMCs into immunocompromised mice
Novel therapies that suppress pathogenic antibody production or accelerate their clearance-such as B-cell depletion therapy,
targeting CAR T cells eliminate antigen
immune-mediated necrotizing myopathy: Progress and therapeutic implications
apoptosis, the release of further antigens and the recruitment of T cells
BCMA-directed therapy can fail due to weak expression
escape and tumor heterogeneity, as well as on-target off-tumor effects
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Paolo CaimiMD
BAFF CAR-T(Paolo Caimi, MD)은 FRα 표적 세포·유전자 치료로, Relapsed CLL; Refractory CLL 영역에서 개발·상용화 중입니다. 작용기전: targeting CAR T cells eliminate antigen. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 15건의 관련 임상이 등록되어 있습니다. 차별점: Novel therapies that suppress pathogenic antibody production or accelerate their clearance-such as B-cell depletion therapy,.
FRα
Relapsed CLL; Refractory CLL
Recruiting
CAR T cells eliminate antigen-low myeloma in an immunocompetent m
AAV) is now recognized as a complex immune-mediated inflammatory disorder rather th
humanized mouse model developed by injecting patient PBMCs into immunocompromised mice
Novel therapies that suppress pathogenic antibody production or accelerate their clearance-such as B-cell depletion therapy,
targeting CAR T cells eliminate antigen
immune-mediated necrotizing myopathy: Progress and therapeutic implications
apoptosis, the release of further antigens and the recruitment of T cells
BCMA-directed therapy can fail due to weak expression
escape and tumor heterogeneity, as well as on-target off-tumor effects
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.